Related references
Note: Only part of the references are listed.Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II)
Brian B. Hasinoff et al.
BIOCHEMICAL PHARMACOLOGY (2015)
AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress
Shrivani Sriskanthadevan et al.
BLOOD (2015)
The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)
Brian B. Hasinoff et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2014)
BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells
Eleni D. Lagadinou et al.
CELL STEM CELL (2013)
Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma
Steven J. O'Day et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol
Ronald K. Blackman et al.
PLOS ONE (2012)
Mitochondrial Respiration - An Important Therapeutic Target in Melanoma
Michelle Barbi de Moura et al.
PLOS ONE (2012)
Inhibition of Mitochondrial Translation as a Therapeutic Strategy for Human Acute Myeloid Leukemia
Marko Skrtic et al.
CANCER CELL (2011)
Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma
Steven O'Day et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Elesclomol induces cancer cell apoptosis through oxidative stress
Jessica R. Kirshner et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors
Anna Berkenblit et al.
CLINICAL CANCER RESEARCH (2007)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis
MI Koukourakis et al.
BRITISH JOURNAL OF CANCER (2003)
Share Paper
